The Geneva pharmaceutical group, Serono, saw its turnover increase by more than 15 per cent in 2000. Sales were $1.147 billion (SFr1.87 billion) last year.This content was published on January 23, 2001 - 11:44
According to figures released on Tuesday, sales of almost all the company's products increased. Just two products accounted for over half of them.
Sales of Rebif, used to treat multiple sclerosis,, almost doubled, reaching $254.2 million, while the Gonal-F fertility drug progressed 12.3 per cent, accounting for $365.9 million of Serono's turnover.
Sales growth was 15.5 per cent in the United States, 16.3 in Europe and 12.8 in the rest of the world. Turnover in the fourth quarter of 2000 was a record $300.3 million, nearly 12 per cent over the previous year.
swissinfo with agencies
This article was automatically imported from our old content management system. If you see any display errors, please let us know: firstname.lastname@example.org